{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"75.1","value":"40.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"55.0","value":"25.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Overall survival was defined as the time interval from treatment initiation to death from any cause or to date of last follow-up for survivors. Survival was estimated using the method of Kaplan and Meier. The 1-year estimate of survival is reported with a 95% confidence interval; estimates are reported by dose level. Stratum 2 patients were those with newly diagnosed diffuse intrinsic pontine glioma (DIPG).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 2, Dose Level 3"}],"paramType":"NUMBER","populationDescription":"Newly diagnosed DIPG patients who were enrolled on Stratum 2 and received at least one dose of APX005M were included in this analysis.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Survival for Stratum 2 (DIPG) Patients","type":"SECONDARY","unitOfMeasure":"Percent probability"}